Latest Cultivation News

Page 1 of 11
Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
Ada Torres
Ada Torres
18 Nov 2026
Ocean Sciences has completed its first direct seaweed shipment from Indonesia to China, but ended September with just A$72,000 in cash and an estimated 0.4 quarters of funding. The company says it expects to raise capital in November as it develops its trading operations and Takalar innovation centre.
Victor Sage
Victor Sage
30 Oct 2026
ASF Group finished FY2026 with A$5.19 million in cash, no outstanding borrowings and a materially stronger net asset position after selling several investments. But the A$4.09 million profit was still largely disposal-led, while operating cash flow remained negative and recurring revenue declined.
Victor Sage
Victor Sage
27 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
ECS Botanics is taking six Australian-grown medicinal cannabis flower products into the UK through Curaleaf Laboratories, with initial supply targeted for November. The two-year deal offers access to UK sell-through but no guaranteed volumes, revenue or minimum purchases.
Victor Sage
Victor Sage
7 Oct 2026
Ocean Sciences delivered a sharp increase in seaweed revenue during FY2026, but the audited report also records a A$1.612 million continuing-operations loss, A$2.319 million operating cash outflow and material uncertainty over its ability to continue as a going concern. The renamed ASX-listed group is now seeking up to A$3 million while building out its Indonesian platform.
Ada Torres
Ada Torres
29 Sept 2026
Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.
Ada Torres
Ada Torres
22 Sept 2026
Hydrix is ramping up its defence technology efforts, focusing on sensing and autonomous systems aligned with Australia’s $425 billion 2026 National Defence Strategy. The company is developing internal prototypes and forging partnerships to commercialise intellectual property in counter-drone and ISR applications.
Sophie Babbage
Sophie Babbage
31 Aug 2026
ECS Botanics boosted revenue by 10% to $21.4 million in FY26, delivering positive EBITDA and operating cash flow while advancing international market entry and branded product growth.
Ada Torres
Ada Torres
28 Aug 2026
Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.
Victor Sage
Victor Sage
28 Aug 2026
Atlas Pearls Ltd (ASX: ATP) faced a tough FY26 with revenue down 42% to $25.8 million and a net loss of $7.9 million, driven by lower pearl quality and softer market conditions. Despite this, the company seeded a record number of oysters and declared a fully franked final dividend of 0.45 cents per share.
Ada Torres
Ada Torres
26 Aug 2026
Rua Bioscience has gained regulatory approval in New Zealand for five new medicinal cannabis products, setting the stage for domestic sales and advancing its strategy to integrate local cannabis genetics.
Ada Torres
Ada Torres
4 Aug 2026

Browse the archive

Full archive